Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects at least 18 years of age.~2. Ability to understand and the willingness to sign a written informed consent.~3. Histological or biopsy proven NSCLC.~4. ECOG performance status of 0-3.~5. Node negative (T1 to T3N0M0), centrally located (within 2cm in all directions around the proximal bronchial tree, including ultra-central tumors, abutting the bronchial tree or trachea) or large (\>1-7cm) Non-Small Cell Lung Cancer (NSCLC), judged acceptable for SBRT by the treating Investigator~6. Adequate end-organ function, based on routine clinical and laboratory workup:~   1. ANC \>1,000 cells/µl, Platelets ≥ 75,000 cells/µl, Hemoglobin ≥ 7.0 g/dl~  2. Serum creatinine ≤ 2 x ULN or calculated creatinine clearance ≥ 30 ml/min~  3. Total bilirubin ≤ 1.5 x ULN (or direct bilirubin below the ULN), AST and ALT ≤ 2.5 x ULN~7. Males and females of must agree to use effective contraception starting prior to the first day of treatment and continuing after the last dose of GC4711/Placebo for 30 days (females) and 90 days (males).~Exclusion Criteria:~1. Subjects with confirmed nodal and/or distant disease(including brain), according standard workup by local investigator~2. Subjects with peripheral lesions 1cm or smaller~3. Prior treatment with immunotherapy within 3 months prior to Day 1 dosing.~4. Prior intra-thoracic radiotherapy or surgery with substantial overlap to planned radiation fields as determined by the treating radiation oncologist.~5. Subjects not recovered/controlled from prior treatment-related (chemotherapy or targeted therapy) toxicities judged by treating physician.~6. Uncontrolled malignancy other than lung cancer that requires active treatment or is deemed by the treating physicians to be likely to affect the subject's survival duration.~7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to GC4711.~8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.~9. Participation in other clinical trials actively testing new anti-cancer treatments, unless previously written approval is provided by the Sponsor.~10. Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure.~11. Female subjects who are pregnant or breastfeeding.~12. Any other conditions that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 GC4711 + SBRT (Type: EXPERIMENTAL): None
- Phase 2 Placebo + SBRT (Type: PLACEBO_COMPARATOR): None
- Phase 2 GC4711 +SBRT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy